CytomX Therapeutics Inc (NASDAQ:CTMX) – Analysts at Wedbush issued their FY2022 earnings per share estimates for CytomX Therapeutics in a research note issued to investors on Thursday, Zacks Investment Research reports. Wedbush analyst R. Driscoll anticipates that the biotechnology company will post earnings of $3.32 per share for the year.
Several other equities analysts have also recently issued reports on the company. BidaskClub cut CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald set a $40.00 price objective on CytomX Therapeutics and gave the company a “buy” rating in a report on Saturday, March 17th. Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 12th. Jefferies Group upped their price target on CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Finally, Bank of America upped their price target on CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $37.86.
Shares of CTMX stock traded down $0.53 on Friday, hitting $27.92. The company had a trading volume of 440,040 shares, compared to its average volume of 382,689. The stock has a market cap of $1,098.49, a PE ratio of -24.07 and a beta of 0.91. CytomX Therapeutics has a twelve month low of $13.00 and a twelve month high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.45. The business had revenue of $27.07 million for the quarter, compared to the consensus estimate of $10.70 million. CytomX Therapeutics had a negative return on equity of 71.42% and a negative net margin of 60.17%.
Large investors have recently bought and sold shares of the business. Macquarie Group Ltd. purchased a new stake in CytomX Therapeutics during the 3rd quarter worth approximately $107,000. Bank of Montreal Can purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $124,000. Voya Investment Management LLC purchased a new stake in CytomX Therapeutics during the 2nd quarter worth approximately $203,000. MetLife Investment Advisors LLC purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $245,000. Finally, Nationwide Fund Advisors increased its stake in CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after buying an additional 4,622 shares in the last quarter. Institutional investors own 78.07% of the company’s stock.
In related news, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction dated Monday, March 26th. The stock was sold at an average price of $31.93, for a total value of $159,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean A. Mccarthy sold 13,052 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $21.04, for a total value of $274,614.08. Following the completion of the transaction, the insider now directly owns 17,695 shares of the company’s stock, valued at approximately $372,302.80. The disclosure for this sale can be found here. Insiders sold a total of 132,626 shares of company stock valued at $3,758,030 in the last ninety days. 8.00% of the stock is currently owned by insiders.
WARNING: This article was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://theenterpriseleader.com/2018/04/02/cytomx-therapeutics-inc-nasdaqctmx-expected-to-post-fy2022-earnings-of-3-32-per-share.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.